BioCurex, Inc.(fka BOCX)

[opportunityknocking]

This study was conducted in conjunction with the Blokhin Cancer Research Centre, Moscow, Russia.

The results of this study showed that 80.4% of ovarian cancers (Stages I-III) were detected with 88% specificity. The samples included 64 normal controls, 51 serum samples from patients with ovarian cancer (25 samples at Stage I and II (b-c) and 26 samples at Stage III (b-c)). The device used in the research was similar to the common pregnancy test kit and represents a potential breakthrough of great magnitude in simplifying cancer detection.

These results show that a rapid lateral flow chromatography test based on the RECAF (tm) marker can discriminate well between cancer and normal samples. When applied to the examples of early-stage ovarian cancer, the rapid test demonstrated better performance than CA-125.

Inverness is fully committed, and unless you can prove otherwise you are misguiding investors.